A Partnership Built to Last: Eppendorf Renews Founding Sponsorship with LabCentral
- The Eppendorf Group and LabCentral have renewed their decade-long relationship for an additional five years.
- Strategically placed Eppendorf equipment and consumables at LabCentral enables reliable results for startups, contributing to scientific milestones to being reached quicker.
Hamburg/Cambridge, March 27, 2024 – The globally active Eppendorf Group proudly announces the 5-year partnership renewal with LabCentral, a renowned life sciences incubator, dedicated to empowering innovative biotech startups. As a Partner since 2014 and Founding Sponsor since 2019, the Eppendorf Group continues its commitment to fostering scientific breakthroughs and supporting the next generation of biotech innovators.
"Eppendorf is proud to continue its relationship as a Founding Sponsor with LabCentral, affirming our shared vision for advancing scientific excellence and empowering researchers to make groundbreaking discoveries", says Dennis Barger, President Market Region Americas, Eppendorf. "Together, we continue to shape the future of life sciences, where collaboration is the catalyst for transformative breakthroughs."
LabCentral is a community of entrepreneurs and scientists dedicated to creating the next generation of groundbreaking science and technology. The Eppendorf Group is a leading life science company that develops, produces, and distributes systems for use in laboratories around the world. Through the partnership, the Eppendorf Group provides a range of equipment, including freezers, shakers, incubators, cyclers, centrifuges, automation, bioprocess, and pipettes, placed within LabCentral's shared facilities. This provides startups immediate access to high quality instrumentation, ensuring they can run experiments day one of residency.
"As a longtime strategic Founding Sponsor to LabCentral, Eppendorf has built a strong reputation for excellence both inside our labs as well as in our resident community", shares Johannes Fruehauf, MD, PhD, President and Executive Director LabCentral. "We are thrilled to extend this collaboration towards our shared mission to improve human health by building biotechs better, faster, and more efficiently."
LabCentral occupies six sites in Massachusetts, USA, continually expanding since being established in 2013. 21% of biopharma Series A funds in 2022 in the US has been awarded to companies affiliated with LabCentral and its resident and alumni companies have raised nearly $23 billion in total funding, creating 5,800 new jobs since 2013. The premier shared lab community is home to more than 100 companies ranging from a single employee to teams of 30 or more. LabCentral offers an ideal space and infrastructure for biotech startups to focus on building their company and developing their science. The future of medicine starts at this leading incubator with the resident innovators and Eppendorf as a premium solutions provider.
About the Eppendorf Group
Eppendorf is a leading life science company that develops, produces, and distributes systems for use in laboratories around the world.
The product portfolio of the business units Liquid Handling, Consumables, Separation & In-strumentation and Bioprocess includes, for example, pipettes, pipette tips, centrifuges, mix-ers, ultra-freezers and bioreactors for cell and gene research. In addition, Eppendorf offers a wide range of high-quality consumables. In fiscal year 2022, the Eppendorf Group generated €1.23 billion in sales and invested €76 million in research and development (R&D).
Eppendorf products are used in academic or industrial research laboratories, such as phar-maceutical, biotech, chemical, and food industries, as well as clinical, environmental, foren-sic, and industrial laboratories for process analysis, production, and quality assurance.
Since 1945, the Eppendorf Group has been headquartered in Hamburg, Germany, and today operates production and R&D sites in Europe, Asia and North America and has subsidiaries in 33 countries. Today, the Group employs more than 5,000 people worldwide. They all act in accordance with the purpose of the company's founders: to improve human living conditions.
Media Contact:
Sabrina Stock
Eppendorf Group SE & Co. KG
Barkhausenweg 1
22339 Hamburg, Germany
E-Mail: stock.s@eppendorf.de
About LabCentral
A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high potential life-sciences and biotech startups. Operating a total of 225,000 square-feet in the heart of Kendall Square in Cambridge, Mass., LabCentral offers fully permitted laboratory and office space for as many as 100 startups comprising approximately 1,000 scientists and entrepreneurs. More information is available at www.labcentral.org.